Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

Leena Gandhi, D. Ross Camidge, Moacyr Ribeiro De Oliveira, Philip Bonomi, David Gandara, Divis Khaira, Christine L. Hann, Evelyn M. McKeegan, Elizabeth Litvinovich, Philip M. Hemken, Caroline Dive, Sari H. Enschede, Cathy Nolan, Yi Lin Chiu, Todd Busman, Hao Xiong, Andrew P. Krivoshik, Rod Humerickhouse, Geoffrey I. Shapiro, Charles M. Rudin

Research output: Contribution to journalArticlepeer-review

418 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences